Post Kala-Azar Dermal Leishmaniasis Following Treatment with 10 mg/kg of Single Dose AmBisome for ..

Control of Post-Kala-Azar Dermal Leishmaniasis (PKDL) patients is one of the top concerns due to their substantial role in the transmission and recurrence of visceral leishmaniasis (VL) epidemics. Because the Single Dose AmBisome 10 mg/kg (SDA) became the obvious choice for the treatment of VL, 896 patients were included in this trial to see if they were at risk of acquiring PKDL. Thirty-three percent (3.35%) of the treated individuals were found to have PKDL with clinical symptoms. Macular lesions were found in 53.33 percent of male patients and 46.67 percent of female patients, with a median time (interquartile range [IQR]) to development of 13.5 (9–23.5) and 23 (9-17) months following therapy, respectively. There were no significant connections found between any patient's demographics and clinical features. Females, on the other hand, were substantially younger than males among patients with confirmed PKDL. According to this study, the rate of PKDL manifestation is directly related to 10 mg/kg of SDA, implying that doses during therapy should be monitored more closely.

Please see the link :- https://www.journalijtdh.com/index.php/IJTDH/article/view/30385